Trial Profile
Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Ibrutinib (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- 07 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 Jun 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.
- 13 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.